No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RLAY240517P22500
- 12.70
- 0.000.00%
15min DelayClose Sep 7 09:31 ET
0.00High0.00Low
0.00Open12.70Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover999.71%IV-1.02%PremiumMay 17, 2024Expiry Date16.14Intrinsic Value100Multiplier3DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.7979Delta0.0462Gamma0.39Leverage Ratio-0.2378Theta-0.0016Rho-0.31Eff Leverage0.0017Vega
Intraday
- 5D
- 1D
News
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and
Relay Therapeutics Upgraded by Barclays Ahead of Data Readout
Express News | Barclays Upgrades Relay Therapeutics to Overweight, Maintains Price Target to $15
Express News | Relay Therapeutics Inc : Barclays Raises to Overweight From Equal Weight
Optimistic Buy Rating for Relay Therapeutics: Pipeline Progress and Financial Stability Drive Analyst Confidence
Relay Therapeutics Price Target Maintained With a $24.00/Share by JMP Securities
Relay Therapeutics Price Target Maintained With a $24.00/Share by JMP Securities
Comments
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
9
Analysts' downgrade of Relay Therapeutics' revenue estimates and prediction of an accelerated decline in revenues compared to industry average growth rate suggest a bearish outlook. The unchanged price target implies business performance in line with expectations despite downward sales forecast adjustment.
$Microsoft(MSFT.US$ $C3.ai(AI.US$ $Alphabet-C(GOOG.US$ $Exscientia(EXAI.US$ $Relay Therapeutics(RLAY.US$
Oppenheimer strategist John Stoltzfus has outlined 10 predictions for the transformative impact of generative AI across various industries. The key focus of generative AI lies in its revolutionary potential to create entirely novel designs and products that may surpass human imagination.
1. Healthcare Augm...
Oppenheimer strategist John Stoltzfus has outlined 10 predictions for the transformative impact of generative AI across various industries. The key focus of generative AI lies in its revolutionary potential to create entirely novel designs and products that may surpass human imagination.
1. Healthcare Augm...
2
$Relay Therapeutics(RLAY.US$ Check this! Revenue 25.2M, up from 344K YoY! and EPS was -.54 versus estimated was -.83! I Like it. And im watching to see if the market likes it?![]()
Read more